The epiCard ®
Intelliject"s epiCard ® is the first significant innovation in the epinephrine auto-injector market in over 25 years. Designed by patients at risk for anaphylaxis, it utilizes the smallest, safest, and most user-friendly drug delivery system ever developed. As a result of Intelliject"s human factors engineering design expertise and strong intellectual property platform, epiCard ® is a patient-centric prescription product that will allow the at-risk patient to manage his/her severe allergic emergency with confidence, and without fear.
* The epiCard ® is in late stages of development.
1. epiCard ®: The Problem Statement
2. The epiCard ®: Device
3. The PromptSystem™
What We Do
Resources
We are committed to raising awareness of the incidence of severe allergies. For more information, link to:
- www.fightsevereallergy.com
- www.foodallergy.org
- www.aaaai.org/patients
/gallery/anaphylaxis.asp - www.acaai.org/public
/advice/anaph.htm
This website is intended solely for entities that are potential commercial partners of Intelliject, Inc. Members of the public, patients and healthcare professionals should not enter this website.
Intelliject currently has no approved products and nothing herein should be considered a promotional claim.
All information contained herein is intended to assist interested parties in assessing possible commercial relationships with Intelliject, Inc. All information is believed to be correct at the date of posting but may change at any time.
